Investigation of Dual-HER2 Blockage Therapy in HER2-Positive Breast Cancer (exploratory randomized P-II)

Trial Profile

Investigation of Dual-HER2 Blockage Therapy in HER2-Positive Breast Cancer (exploratory randomized P-II)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2016

At a glance

  • Drugs Lapatinib (Primary) ; Antihormones; Paclitaxel; Trastuzumab
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms NeoLath
  • Most Recent Events

    • 07 Jun 2016 Interim results of 222 tumor samples from 74 patients presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 27 Apr 2015 Planned End Date changed from 1 Sep 2018 to 31 Dec 2019 as reported by University Hospital Medical Information Network - Japan record.
    • 28 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top